UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

December 1, 2017: By Joan McKenna

ExonateUK-based Exonate, an early stage company developing an eye drop treatment for wet AMD and diabetic macular edema, has formed a clinical advisory board of five ophthalmic experts.

Exonate’s preclinical compounds are designed to inhibit a protein kinase called SRPK1, which promotes production of vascular endothelial growth factor (VEGF), driving angiogenesis and retinal disease progression.

The five members of the advisory board are:

—Peter Adamson, PhD, head of ophthalmology research and development at Netherlands-based ProQR Therapeutics;

—Lloyd Paul Aiello, MD, PhD, professor of ophthalmology at Harvard Medical School and founding chair of the National Eye Institute Diabetic Retinopathy Clinical Research Network;

—Peter Campochiaro, MD, professor of ophthalmology at the Johns Hopkins Wilmer Eye Institute;

—Usha Chakravarthy, MD, professor of ophthalmology at Queen’s University Belfast, internationally known for research of the molecular mechanisms of AMD and diabetic retinopathy;

—Robyn Guymer, MBBS, PhD, professor of ophthalmology at Melbourne University, deputy director of the Centre for Eye Research Australia, and a senior retinal specialist at the Royal Victorian Eye and Ear Hospital.

In February, Exonate announced it had been awarded a £4.9 million seeding drug discovery award by the Wellcome Trust, a global charitable foundation, to continue development of its retinal candidates.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023